Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 7 years
- Director since
- 2023
7 years of board service in total across 2 boards, counting each seat separately. Longest: Royalty Pharma plc, 3 years.
Chief executive roles
Outstanding · grade A+
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 100
185.1% a year in revenue
20% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Cibus Inc. June 2, 202699.4%
-
Cibus Inc. May 30, 202499.7%
-
Royalty Pharma plc June 22, 202399.7%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 29, 2026 | Cibus Inc. | Grant or award | +333,333 | $1.50 | $500,000 |
| Jun 9, 2025 | Cibus Inc. | In-the-money exercise | +4,000,000 | — | — |
| Jun 9, 2025 | Cibus Inc. | In-the-money exercise | +50,000 | $0.01 | $500 |
| Jun 5, 2025 | Cibus Inc. | Grant or award | +5,714,286 | $1.75 | $10,000,001 |
| Dec 31, 2024 | Cibus Inc. | Derivative conversion | −1,388,084 | — | — |
| Dec 31, 2024 | Cibus Inc. | Derivative conversion | +1,388,084 | — | — |
| Sep 18, 2024 | Cibus Inc. | Grant or award | +250,000 | $4.00 | $1,000,000 |
| Jun 11, 2024 | Cibus Inc. | Grant or award | +98,040 | $10.20 | $1,000,008 |
| Feb 20, 2024 | Royalty Pharma plc | Derivative conversion | +300,000 | — | — |
| Jan 4, 2024 | Royalty Pharma plc | Open-market sale | −35,702 | $27.55 | $983,590 |
| Jan 3, 2024 | Royalty Pharma plc | Open-market sale | −199,098 | $27.79 | $5,532,933 |
| Jan 2, 2024 | Royalty Pharma plc | Open-market sale | −235,200 | $28.52 | $6,707,904 |
| Dec 29, 2023 | Cibus Inc. | Other | +1,505,967 | — | — |
| Dec 29, 2023 | Cibus Inc. | Derivative conversion | −1,500,000 | — | — |
| Dec 29, 2023 | Cibus Inc. | Derivative conversion | +1,500,000 | — | — |
Questions about Rory B. Riggs
What boards is Rory B. Riggs on?
Rory B. Riggs sits on the boards of Cibus Inc. and Royalty Pharma plc.
What company is Rory B. Riggs the CEO of?
Rory B. Riggs has been Chief Executive Officer of Cibus Inc. since May 2023.
How long has Rory B. Riggs served on boards?
Our records show at least 7 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.